Stock Traders Purchase Large Volume of Abivax Call Options (NASDAQ:ABVX)

Abivax SA Sponsored ADR (NASDAQ:ABVX) saw some unusual options trading activity on Monday. Stock traders acquired 16,006 call options on the company. This is an increase of approximately 100% compared to the typical volume of 7,985 call options.

Abivax Price Performance

Shares of ABVX traded up $3.15 during midday trading on Monday, reaching $102.30. 1,676,856 shares of the stock were exchanged, compared to its average volume of 1,437,922. The business’s 50-day moving average price is $114.06 and its 200 day moving average price is $118.16. Abivax has a twelve month low of $5.69 and a twelve month high of $148.83. The company has a market capitalization of $8.16 billion, a price-to-earnings ratio of -19.62 and a beta of 0.69.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. As a group, equities research analysts expect that Abivax will post -3.4 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on ABVX. Citizens Jmp boosted their price objective on Abivax from $131.00 to $187.00 and gave the company a “market outperform” rating in a report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. Wall Street Zen upgraded shares of Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. BTIG Research reissued a “buy” rating and set a $150.00 price target on shares of Abivax in a research report on Tuesday, June 16th. Finally, Wolfe Research set a $136.00 price objective on shares of Abivax in a report on Wednesday, June 3rd. Twelve analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $130.08.

Institutional Investors Weigh In On Abivax

Hedge funds and other institutional investors have recently made changes to their positions in the business. GHP Investment Advisors Inc. increased its holdings in shares of Abivax by 155.6% in the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock valued at $26,000 after acquiring an additional 140 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after purchasing an additional 369 shares during the last quarter. Bank of America Corp DE boosted its holdings in Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after purchasing an additional 344 shares during the period. Finally, WPG Advisers LLC increased its stake in Abivax by 125.9% during the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares during the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.